María del Carmen Rodríguez-Salazar

María del Carmen Rodríguez-Salazar

Auto-generated profile, based on publicly available information

María del Carmen Rodríguez-Salazar

Department of Clinical Laboratory, Faculty of Chemistry, Universidad Autónoma de Coahuila

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2017 in Oncology Letters
Verified
Journal Article
Open access
PDF file
MRMaria del Carmen Rodríguez-Salazar
Maria del Carmen Rodríguez-Salazar
MMMoisés Armides Franco Molina
Moisés Armides Franco Molina
EMEdgar Mendoza-Gamboa
Edgar Mendoza-Gamboa
AMAna Carolina Martinez-Torres
Ana Carolina Martinez-Torres
PZPablo Zapata-Benavides
Pablo Zapata-Benavides
CRCristina Rodríguez-Padilla
Cristina Rodríguez-Padilla
Immunogenic cell death is a cell death modality that stimulates the immune system to combat cancer cells. IMMUNEPOTENT CRP (ICRP) is a mixture of substances of low molecular weight obtained from bovine spleens that exhibits in vitro cytotoxic activity on different tumor cell lines and modulates the immune response in vivo. The aim of the present study was to determine whether the cytotoxic effect of ICRP and its combination with oxaliplatin (OXP) on murine melanoma B16F10 cells was due to immunogenic cell death. The cytotoxic assay was performed using flow cytometry to detect Annexin V and propidium iodide staining, and calreticulin (CRT) exposure. Adenosine triphosphate, heat shock protein (HSP) 70, HSP90 and high mobility group box 1 (HMGB1) release were identified using bioluminescence, western blot and ELISA assays, respectively. The present in vitro study demonstrated that treatments with ICRP or OXP induced cell death in a time-dependent manner, but treatment with the combination of ICRP + OXP increased the cytotoxic effect following 24 h of treatment. CRT exposure and release of adenosine triphosphate (ATP), HSP70, HSP90 and HMGB1 were induced by treatment with ICRP, and the combination of ICRP + OXP increased the exposure and release of damage-associated molecular patterns (DAMPs), while OXP treatment only induced CRT exposure, ATP and HMGB1 release. The in vivo experiments demonstrated that administration of tumor-derived DAMP-rich cell lysates derived from B16F10 cells treated with ICRP and the combination of ICRP + OXP prevented melanoma growth; however, OXP treatment did not. These results suggested that IMMUNEPOTENT CRP may be used as an agent to increase the ability of antitumor drugs to induce immunogenic cell death and prevent the growth of melanoma.

1 January 2016 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
ECErika Evangelina Coronado-Cerda
Erika Evangelina Coronado-Cerda
MMMoisés Armides Franco Molina
Moisés Armides Franco Molina
EMEdgar Mendoza-Gamboa
Edgar Mendoza-Gamboa
HPHeriberto Prado-Garcia
Heriberto Prado-Garcia
LRLydia Guadalupe Rivera-Morales
Lydia Guadalupe Rivera-Morales
CRCristina Padilla Rodríguez-Padilla
Cristina Padilla Rodríguez-Padilla
Chemotherapy treatments induce a number of side effects, such as leukopenia neutropenia, peripheral erythropenia, and thrombocytopenia, affecting the quality of life for cancer patients. 5-Fluorouracil (5-FU) is wieldy used as myeloablative model in mice. The bovine dialyzable leukocyte extract (bDLE) or IMMUNEPOTENT CRP® (ICRP) is an immunomodulatory compound that has antioxidants and anti-inflammatory effects. In order to investigate the chemoprotection effect of ICRP on bone marrow cells in 5-FU treated mice, total bone marrow (BM) cell count, bone marrow colony forming units-granulocyte/macrophage (CFU-GM), cell cycle, immunophenotypification, ROS/superoxide and Nrf2 by flow cytometry, and histological and hematological analyses were performed. Our results demonstrated that ICRP increased BM cell count and CFU-GM number, arrested BM cells in G0/G1 phase, increased the percentage of leukocyte, granulocytic, and erythroid populations, reduced ROS/superoxide formation and Nrf2 activation, and also improved hematological levels and weight gain in 5-FU treated mice. These results suggest that ICRP has a chemoprotective effect against 5-FU in BM cells that can be used in cancer patients.

17 July 2024 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
JPJoan Poblano
Joan Poblano
ICIleana Castillo-Tobías
Ileana Castillo-Tobías
Lia BerlangaLia Berlanga
Lia Berlanga
Maria Concepcion Tamayo-OrdóñezMaria Concepcion Tamayo-Ordóñez
Maria Concepcion Tamayo-Ordóñez
MRMaría del Carmen Rodríguez‐Salazar
María del Carmen Rodríguez‐Salazar
Luis Enrique Cobos PucLuis Enrique Cobos Puc
Luis Enrique Cobos Puc

9 April 2018 in Biotechnology & Biotechnological Equipment
Verified
Journal Article
Open access
MMMoisés Armides Franco Molina
Moisés Armides Franco Molina
SSSilvia Santana-Krímskaya
Silvia Santana-Krímskaya
ECErika E. Coronado-Cerda
Erika E. Coronado-Cerda
CLCarlos Eduardo Hernández Luna
Carlos Eduardo Hernández Luna
DTDIANA ZARATE TRIVIÑO
DIANA ZARATE TRIVIÑO
CRCristina Rodríguez-Padilla
Cristina Rodríguez-Padilla
IMMUNEPOTENT CRP is a dialyzable leukocyte extract obtained from bovine spleen with immunomodulatory and antitumour properties; therefore, when administrated as an adjuvant therapy for cancer patients, it has increased their survival and quality of life. The bioavailability of any orally administered compound can be reduced due to gastrointestinal enzymes. In this study, we evaluated if IMMUNEPOTENT CRP is resistant to the treatment with different enzymes (proteases, nucleases, polysaccharide-degrading enzymes or lipase), using as parameters for biological activity measurement its in vitro antitumour and antioxidant properties and in vivo the antitumour effect of IMMUNEPOTENT CRP treated with proteinase K. In conclusion, we consider necessary to include the antioxidant and cytotoxic activity on the MCF-7 cancer cell line as parameters for the quantitative determination of biological activity or potency tests for batch release. Additionally, the results showed that different enzymatic treatments do not affect the antitumour and antioxidant activities of IMMUNEPOTENT CRP in vitro, suggesting that this product can be administered orally without any loss of biological activity. Furthermore, IMMUNEPOTENT CRP treatment with proteinase K increases the antitumour activity in vivo.

28 December 2016 in Journal of Nanomaterials
Verified
Journal Article
Open access
PDF file
MMMoisés Armides Franco Molina
Moisés Armides Franco Molina
EME. Mendoza-Gamboa
E. Mendoza-Gamboa
DTDIANA ZARATE TRIVIÑO
DIANA ZARATE TRIVIÑO
ECE. E. Coronado-Cerda
E. E. Coronado-Cerda
JAJ. M. Alcocer-González
J. M. Alcocer-González
CRC. Rodríguez-Padilla
C. Rodríguez-Padilla
Colloidal silver (AgC) is currently used by humans and it can be internalized through inhalation, injection, ingestion, and dermal contact. However, there is limited information about immunological activity; more investigations using colloidal silver are needed. In the present study, the effects of AgC (17.5 ng/mL) on immunological parameters (proliferation and immunophenotyping) using human peripheral blood mononuclear cells (PBMC) and macrophages (phagocytosis) and cytotoxicity on leukemia and lymphoma cancer cell lines (1.75 to 17.5 ng/mL) were investigated. AgC was observed to significantly (p<0.05) decrease interleukin-2 (IL-2) production and proliferation induced by phytohemagglutinin or concanavalin A in PBMC without affecting its cell viability but with cytotoxic effect on cancer cells. IL-2, IL-4, IL-6, IL-10, INF-γ, and IL-17A cytokines production and CD3+, CD3−CD19+, CD3+CD4+, CD3+CD8+, and CD16+CD56+ PBMC phenotypes were not affected by AgC. The present study demonstrates that colloidal silver is harmless and nontoxic to the immune system cells and its ability to interfere with the immune response by decreasing cell proliferation when stimulated with mitogens demonstrated the antilymphoproliferative potential of AgC.

19 July 2019 in Current Nanoscience
Verified
Journal Article
Open access
PDF file
MMMoisés Armides Franco Molina
Moisés Armides Franco Molina
ECErika Evangelina Coronado-Cerda
Erika Evangelina Coronado-Cerda
ELEdgar López-Pacheco
Edgar López-Pacheco
DTDIANA ZARATE TRIVIÑO
DIANA ZARATE TRIVIÑO
SGSergio Arturo Galindo-Rodríguez
Sergio Arturo Galindo-Rodríguez
CRCristina Rodríguez-Padilla
Cristina Rodríguez-Padilla
Background: Immunotherapy involving dendritic cells (DC) has been used to treat cancer with satisfactory results. The generation of mature dendritic cells derived from monocytes, however, is expensive because of the use of cytokines.Objective: To reduce DC therapy costs, it is important to evaluate lower-cost materials capable of inducing dendritic cell maturation; for this purpose, we synthetized chitosan nanoparticles.Methods: Chitosan nanoparticles were synthetized by ionic gelation and characterized using dynamic light scattering, laser Doppler electrophoresis, transmission electron microscopy and infrared spectrum. Endotoxin levels were determined by Limulus amoebocyte lysate. The biological effect was evaluated by microscopy, immunophenotypification, cellular viability and phagocytosis assays.Results: We synthetized endotoxin-free chitosan nanoparticles with an average size of 208 nm and semi-spherical morphology. The nanoparticles induced changes in monocyte morphology, surface marker expression and phagocytosis that correlate with those of DC. These preliminary results demonstrate that chitosan nanoparticles can induce monocyte differentiation into immature dendritic cells and, when combined with albumin and keyhole limpet hemocyanin, they can induce dendritic cell maturation.Conclusion: We conclude that chitosan nanoparticles are a suitable alternative for lower-cost DC immunotherapy generation, provided that our results be corroborated in vivo.